What is Evommune 's convertible debt (non-current)?

Evommune (EVMN) reported convertible debt (non-current) of $837.8K in Q1 2026.

What does convertible debt (non-current) mean?

This represents the principal amount of debt instruments that can be converted into equity, with maturity dates extending beyond one year. It is a common financing tool for biotechnology companies to raise capital while deferring potential dilution. Investors analyze this to assess the company's long-term debt burden and the potential for future equity dilution upon conversion.

Evommune EVMN Convertible Debt (Non-Current)

Convertible Debt (Non-Current) at other companies

Hims & Hers HealthHIMS

$974.11M—

Other financials

Income statement

See full

Revenue$1.6M+3.5%

Gross profit$961.1K+10.9%

Operating income-$682.8K-2,027%

Net income-$7.0M-5,414%

EPS (diluted)-$0.36-1,700%

Balance sheet

See full

Cash & equivalents$1.1M+401%

Total debt$2.0M—

Total equity-$4.5M-3,048%

Total assets$7.2M—

Cash flow

See full

Operating cash flow-$424.6K-341%

CapEx$1.0-99.8%

Free cash flow-$2.7M-4,996%

Valuation

See full

Market cap$848.59M+39.5%

Enterprise value$849.52M—

P/S127.3×—

Profitability

See full

Gross margin53.7%—

Operating margin-30.7%—

Net margin-90.1%—

Returns & leverage

See full

Return on equity275.7%—

Debt / equity1.4×—

Current ratio1.2×—

Where this comes from

Reported directly by Evommune in its filing.

Tagged under the XBRL concept us-gaap:ConvertibleDebtNoncurrent.

The official record: Evommune ’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Evommune 's convertible debt (non-current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Evommune 's convertible debt (non-current)?: Evommune (EVMN) reported convertible debt (non-current) of $837.8K in Q1 2026.
What does convertible debt (non-current) mean?: This represents the principal amount of debt instruments that can be converted into equity, with maturity dates extending beyond one year. It is a common financing tool for biotechnology companies to raise capital while deferring potential dilution. Investors analyze this to assess the company's long-term debt burden and the potential for future equity dilution upon conversion.